En Zhe Jia Shi Pharmaceutical

Enzhe Jiashi Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. The company utilizes a proprietary drug discovery platform that integrates structural biology and medicinal chemistry to target high-value, challenging proteins. Its lead candidate, EJ001, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor currently in Phase 2 clinical trials for the treatment of psoriasis. The pipeline also includes EJ002, an HPK1 inhibitor for immuno-oncology, and other programs targeting USP1. Enzhe Jiashi aims to provide patients with more effective and safer treatment options through precision drug design.